Danaher Co. (NYSE:DHR) Shares Sold by Smith Salley Wealth Management

Smith Salley Wealth Management reduced its stake in shares of Danaher Co. (NYSE:DHR) by 5.1% in the 2nd quarter, HoldingsChannel reports. The firm owned 842 shares of the conglomerate’s stock after selling 45 shares during the quarter. Smith Salley Wealth Management’s holdings in Danaher were worth $210,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Cary Street Partners Investment Advisory LLC lifted its position in shares of Danaher by 20.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after acquiring an additional 1,533 shares in the last quarter. Caden Capital Partners LP boosted its stake in shares of Danaher by 12.4% during the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after purchasing an additional 15,313 shares during the last quarter. Legacy Financial Advisors Inc. raised its position in shares of Danaher by 2.4% in the fourth quarter. Legacy Financial Advisors Inc. now owns 2,377 shares of the conglomerate’s stock valued at $550,000 after buying an additional 55 shares during the last quarter. JARISLOWSKY FRASER Ltd lifted its stake in shares of Danaher by 10.8% during the fourth quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock valued at $132,524,000 after buying an additional 55,908 shares during the period. Finally, HighPoint Advisor Group LLC acquired a new stake in Danaher during the fourth quarter worth approximately $2,614,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on DHR. Stifel Nicolaus raised their price objective on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Evercore ISI decreased their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Bank of America boosted their price target on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group increased their target price on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Finally, Royal Bank of Canada upped their price target on shares of Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Stock Performance

NYSE DHR traded up $2.29 during trading hours on Friday, reaching $269.31. The company’s stock had a trading volume of 4,595,672 shares, compared to its average volume of 2,803,002. The stock has a market cap of $199.47 billion, a PE ratio of 45.65, a PEG ratio of 4.62 and a beta of 0.83. The business has a 50-day simple moving average of $259.76 and a 200 day simple moving average of $254.94. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.05 EPS. Equities research analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is currently owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.